Results 261 to 270 of about 98,417 (285)

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer

Cancer Cell, 2017
Surendra K Shukla, Vinee Purohit, Kamiya Mehla   +2 more
exaly  

Gemcitabine

Reactions Weekly, 2008
openaire   +1 more source

Gemcitabine resistance in pancreatic ductal adenocarcinoma

Drug Resistance Updates, 2015
Yoav Binenbaum, Shorook Na’Ara, Ziv Gil   +2 more
exaly  

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

Annals of Oncology, 2005
H Oettle, J L Van Laethem, D Von Hoff
exaly  

Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer

Cell Metabolism, 2019
Christopher J Halbrook, Ilya Kovalenko, Ho-Joon Lee   +2 more
exaly  

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Lancet, The, 2017
John P Neoptolemos, Daniel H Palmer, Juan W Valle   +2 more
exaly  

A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study

British Journal of Cancer, 2012
H Isayama, Hirano K, Tada M
exaly  

Gemcitabine

Reactions Weekly, 1998
openaire   +1 more source

Gemcitabine

Reactions Weekly, 2022
openaire   +1 more source

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

British Journal of Cancer, 2007
Yusuke Mizukami, Y Kohgo, Koizumi K
exaly